However, changes in C5aR2 were not correlated with changes in TnT during tocilizumab treatment, and in contrast to C5aR1 expression, the changes in C5aR2 expression in PBMC in the different CAD subgroups were rather modest. The gene discussed is C5AR2; the disease is coronary artery disorder.